0.01 | 2.98%
CARDIUM THERAPEUTICS INC's gross profit margin for the first quarter of its fiscal year 2012 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line.
At the same time, stockholders' equity ("net worth") has greatly increased by 73.49% from the same quarter last year.
| Income Statement | Q1 FY12 | Q1 FY11 |
|---|---|---|
| Net Sales ($mil) | 0.02 | 0.0 |
| EBITDA ($mil) | 0.0 | -1.73 |
| EBIT ($mil) | -2.66 | -1.78 |
| Net Income ($mil) | -2.59 | -1.69 |
| Balance Sheet | Q1 FY12 | Q1 FY11 |
|---|---|---|
| Cash & Equiv. ($mil) | 0.0 | 6.16 |
| Total Assets ($mil) | 11.79 | 7.67 |
| Total Debt ($mil) | 0.0 | 0.0 |
| Equity ($mil) | 10.0 | 5.76 |
| Profitability | Q1 FY12 | Q1 FY11 |
|---|---|---|
| Gross Profit Margin | 75.0 | 0.0 |
| EBITDA Margin | 0.0 | 0.0 |
| Operating Margin | -13300.0 | 0.0 |
| Sales Turnover | 0.0 | 0.03 |
| Return on Assets | -68.13 | -70.25 |
| Return on Equity | -80.36 | -93.46 |
| Debt | Q1 FY12 | Q1 FY11 |
|---|---|---|
| Current Ratio | 0.0 | 3.61 |
| Debt/Capital | 0.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 |
| Interest Coverage | 0.0 | -890.0 |
| Share Data | Q1 FY12 | Q1 FY11 |
|---|---|---|
| Shares outstanding (mil) | 0.0 | 83.1 |
| Div / share | 0.0 | 0.0 |
| EPS | -0.02 | -0.02 |
| Book value / share | 0.0 | 0.07 |
| Institutional Own % | n/a | n/a |
| Avg Daily Volume | 358627.0 | 661284.0 |
SELL. This stock?s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Due to the lack of price valuation ratios for CARDIUM THERAPEUTICS INC, we cannot determine the premium or discount status of the shares at this time.
| Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CXM NM | Peers 31.84 | CXM NA | Peers 26.34 | |||||||||||||||||||||
|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. CXM's P/E is negative making this valuation measure meaningless. |
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures. Ratio not available. |
|||||||||||||||||||||||
| Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
| CXM NA | Peers 30.67 | CXM NA | Peers 0.86 | |||||||||||||||||||||
|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings. CXM's ratio is negative making this valuation measure meaningless. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
| Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
| CXM NA | Peers 17.03 | CXM -33.33 | Peers 17.13 | |||||||||||||||||||||
|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. Ratio not available. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, CXM is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
| Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
| CXM NA | Peers 19.77 | CXM -91.81 | Peers 71.83 | |||||||||||||||||||||
|
Neutral. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. Ratio not available. |
Lower. A sales growth rate that trails the industry implies that a company is losing market share. CXM significantly trails its peers on the basis of sales growth |
|||||||||||||||||||||||


